GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Short-Term Debt & Capital Lease Obligation

Tissue Regenix Group (LSE:TRX) Short-Term Debt & Capital Lease Obligation : £0.51 Mil (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Tissue Regenix Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.51 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Tissue Regenix Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £6.92 Mil.


Tissue Regenix Group Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Tissue Regenix Group's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Short-Term Debt & Capital Lease Obligation Chart

Tissue Regenix Group Annual Data
Trend Jan14 Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.26 0.09 0.93 0.51

Tissue Regenix Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.10 0.93 0.31 0.51

Tissue Regenix Group Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Tissue Regenix Group Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Tissue Regenix Group (LSE:TRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Short-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
Address
Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.

Tissue Regenix Group (LSE:TRX) Headlines

From GuruFocus

Tanzanian Gold Corporation Announces Public Offering of Common Shares

By GlobeNewswire GlobeNewswire 12-16-2019

Doubling of Gold Mineral Resources Confirmed

By GlobeNewswire GlobeNewswire 06-23-2020

Tanzanian Gold Clarifies Disclosure

By GlobeNewswire GlobeNewswire 02-21-2020

Tanzanian Royalty Announces the Sale of Common Shares of $885,734

By GlobeNewswire GlobeNewswire 01-13-2019

TanGold Announces Board and Management Change

By GlobeNewswire GlobeNewswire 01-21-2021